Skip to main content

Carina Masferrer Ferragutcasas

I am a phD student in the Biochemistry, Molecular Biology and Biomedicine program from the Universitat Autònoma de Barcelona. Since 2020 I have been developing my thesis in the Biomedical Research in Gynaecology group at the Vall d'Hebron Institute of Research (VHIR) under the supervision of Dr. Eva Colás. My research aims, on the one hand, to analyse, understand, and work on the molecular profile of patients with endometriosis. On the other hand, it is focused in exploring and improving new treatment strategies for endometrial cancer patients.

Institutions of which they are part

Research technician
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Carina Masferrer Ferragutcasas

Institutions of which they are part

Research technician
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am a phD student in the Biochemistry, Molecular Biology and Biomedicine program from the Universitat Autònoma de Barcelona. Since 2020 I have been developing my thesis in the Biomedical Research in Gynaecology group at the Vall d'Hebron Institute of Research (VHIR) under the supervision of Dr. Eva Colás. My research aims, on the one hand, to analyse, understand, and work on the molecular profile of patients with endometriosis. On the other hand, it is focused in exploring and improving new treatment strategies for endometrial cancer patients.

After studying my bachelor's degree in Biomedical Sciences at Universitat de Barcelona, I pursued the master's programme in Translational Biomedical Research at the Vall d'Hebron Institute of Research (VHIR), aiming to direct my professional career to the clinical field. Due to my interest in gynaecology, I carried out its curricular internship in the Biomedical Research in Gynaecology group, developing the project “Study of Phototrexate as a possible therapeutic agent for endometrial cancer”.

The sponsorship of the "Mocador Solidari" initiative, promoted by Vall d'Hebron with the collaboration of Natura and Judit Mascó as its ambassador, allowed me to join the group as a phD student under the supervision of Dr. Eva Colás. Within this project I am currently working to develop new therapeutic strategies for improving the treatment of endometrial cancer. This cancer is the most common gynaecologic malignancy, accounting for 6% of diagnosed cancers in women. More specifically, we are studying the efficacy of the combination of immunotherapy with the ABTL0812 molecule, which has previously demonstrated good results in this type of cancer. This could specially improve the therapeutic options of patients with aggressive subtypes of endometrial cancer.

Simultaneously, I also collaborate with the clinical team of the hospital's Gynaecology Service to analyse, understand, and work on the molecular profile of patients with endometriosis. We aim to progress and individualize their clinical management, regarding both the diagnostic process and therapeutic options, to improve the quality of life of those patients.

Projects

xx

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Carina Masferrer Ferragutcasas, Fco Javier De la Torre Fdez de Vega, Silvia Cabrera Diaz, Ana Luzarraga Aznar, Lourdes Elena Salazar Huayna
Funding agency: Instituto de Salud Carlos III
Funding: 177500
Reference: PI23/01470
Duration: 01/01/2024 - 31/12/2026

Recerca biomèdica en ginecologia

IP: Antonio Gil Moreno
Collaborators: Natalia Rodriguez Gómez - Hidalgo, Elena Suarez Salvador, Jose Luis Poza Barrasus, Vicente Bebia Conesa, Angel García Jiménez, Maria Asuncion Perez Benavente, Carina Masferrer Ferragutcasas, Eva Colas Ortega, Sabina Salicrú Riera, Anna Ruano Lopez, Fco Javier De la Torre Fdez de Vega, Montserrat Cubo Abert, Silvia Cabrera Diaz, Laura Mañalich Barrachina, Marta Rebull Santamaria, Mireia Armengol Alsina, Ana Luzarraga Aznar, Irene De la Calle Fuentes, José Luis Sánchez Iglesias, Melissa Bradbury Lobato, Beatriz Villafranca Magdalena, Melek Denizli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 01157
Duration: 01/01/2022 - 30/06/2025

A dual liquid biopsy strategy in endometrial cancer: evaluation of risk of recurrence and pesonalized therapy.

IP: Antonio Gil Moreno
Collaborators: Vicente Bebia Conesa, Angel García Jiménez, Carina Masferrer Ferragutcasas, Montserrat Cubo Abert, Mireia Armengol Alsina, Marta Rebull Santamaria, Melek Denizli
Funding agency: Instituto de Salud Carlos III
Funding: 209330
Reference: PI20/01566
Duration: 01/01/2021 - 31/12/2023

ADVANCING ON THE DEVELOPMENT OF A NON-INVASIVE TOOL TO EARLY DIAGNOSE ENDOMETRIAL CANCER

IP: Eva Colas Ortega
Collaborators: Carina Masferrer Ferragutcasas, Fco Javier De la Torre Fdez de Vega, Silvia Cabrera Diaz, Irene De la Calle Fuentes, Beatriz Villafranca Magdalena
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI20/00644
Duration: 01/01/2021 - 31/12/2024

Related news

On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

Related professionals

Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Cañas Perea

Xavier Cañas Perea

Director/a d'Àrea
Clinical Research Development Directorate
Read more
Ruiz Esteve, Fernando

Ruiz Esteve, Fernando

Research technician
Neurovascular Diseases
Read more
Marcos Prieto, Susana

Marcos Prieto, Susana

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.